Important Information for Regeneron Pharmaceuticals, Inc. Securities Buyers: Deadline Approaching for Potential Lawsuit
New York, NY – Rosen Law Firm, a global investor rights law firm, alerts purchasers of Regeneron Pharmaceuticals, Inc. (REGN) securities between November 2, 2023, and October 30, 2024, both dates inclusive (the “Class Period”), of the significant March 10, 2025, lead plaintiff deadline. Investors who purchased Regeneron securities during the Class Period are encouraged to contact the firm.
What Happened?
Regeneron is a leading biotechnology company that develops and commercializes medicines for various diseases. The company’s products include EYLEA, Dupixent, and Arcalyst, among others. However, during the Class Period, Regeneron may have issued materially misleading statements and failed to disclose material information regarding the safety and efficacy of certain of its drugs.
Why is this Important?
If you purchased Regeneron securities during the Class Period, you may be entitled to compensation without payment of any out-of-pocket fees or costs through a contingency fee arrangement. The purpose of the class action is to recover damages for Regeneron investors who have been harmed by the company’s alleged misrepresentations or omissions.
What’s Next?
The lead plaintiff deadline is approaching, and investors who wish to seek potential remedies must act quickly. The lead plaintiff is the representative party in the lawsuit who acts on behalf of all other class members. If you wish to join the class action, you can contact the Rosen Law Firm.
Impact on Individual Investors
If you purchased Regeneron securities during the Class Period, you may have experienced financial losses due to the alleged misrepresentations or omissions by the company. If the lawsuit is successful, you could potentially recover your losses.
Impact on the World
The outcome of this lawsuit could impact the biotechnology industry as a whole, potentially increasing transparency and accountability for companies regarding the safety and efficacy of their drugs. It could also serve as a reminder for investors to carefully research companies before making investment decisions.
Conclusion
If you purchased Regeneron securities between November 2, 2023, and October 30, 2024, and believe that Regeneron may have engaged in securities fraud, you may be entitled to compensation. The lead plaintiff deadline is approaching, so it is essential to act quickly. Contact the Rosen Law Firm for more information on how to join the class action.
The Rosen Law Firm represents investors worldwide, focusing on securities class actions and other complex litigation. The firm combines the expertise and resources of a large law firm with the flexibility and attention to individualized client needs of a boutique firm. For more information, visit
(Please note: This press release is not a solicitation or an offer to buy, sell or hold securities mentioned, and it is not intended to provide investment advice. The Rosen Law Firm encourages all investors to consult their personal investment advisor, or other professional advisor, before making any investment decisions. The Rosen Law Firm is not responsible for the accuracy or completeness of the contents of the press release or for any omissions or errors contained herein.
- Regeneron Pharmaceuticals, Inc.
- NASDAQ: REGN
- Global investor rights law firm
- Securities fraud
- Lead plaintiff deadline
- Compensation for investors
- Biotechnology industry
